Protective effects of rheumatoid arthritis in septic ICU patients

We used the Multiparameter Intelligent Monitoring in Intensive Care II (MIMIC II) database to analyze factors contributing to the mortality of intensive care unit (ICU) patients with severe sepsis. We found that septic patients with rheumatoid arthritis (RA) have significantly lower observed mortality rates than patients without the condition. Further, differences in gender, age, disease severity, and patients' use of corticosteroids did not explain this phenomenon, suggesting that the observed protective effect is specific to RA.

[1]  Peter Groves,et al.  The 'big data' revolution in healthcare: Accelerating value and innovation , 2016 .

[2]  M. Netea,et al.  Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? , 2013, American journal of respiratory and critical care medicine.

[3]  T. Glück.  What Is the True Incidence of Severe Sepsis in the U.S. , 2013 .

[4]  John A Kellum,et al.  Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study , 2013, Critical Care.

[5]  R. Salomão,et al.  Bacterial Sensing, Cell Signaling, and Modulation of the Immune Response During Sepsis , 2012, Shock.

[6]  T. H. Kyaw,et al.  Multiparameter Intelligent Monitoring in Intensive Care II: A public-access intensive care unit database* , 2011, Critical care medicine.

[7]  C. Coopersmith,et al.  Characterization and Modulation of the Immunosuppressive Phase of Sepsis , 2010, Infection and Immunity.

[8]  S. Opal,et al.  Molecular biology of inflammation and sepsis: A primer* , 2009, Critical care medicine.

[9]  Radford M. Neal.  Pattern Recognition and Machine Learning , 2007, Technometrics.

[10]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[11]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[12]  K. Reinhart,et al.  IMMUNE MODULATION AND SEPSIS , 1997, International journal of clinical practice.

[13]  A. Cats,et al.  Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. , 1988, Arthritis and rheumatism.

[14]  A. Cats,et al.  Frequency of infections among rheumatoid arthritis patients, before and after disease onset. , 1987, Arthritis and rheumatism.

[15]  M. Saeed,et al.  Multiparameter Intelligent Monitoring in Intensive Care Ii (Mimic-Ii): A Public-Access Intensive Care Unit Database , 2011 .

[16]  D. Spigel.  The value of observational cohort studies for cancer drugs. , 2010, Biotechnology healthcare.

[17]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[18]  A. Kakrani,et al.  Sequential organ failure assessment score as prognostic marker in critically ill patients in a tertiary care intensive care unit , 2013 .